BiotechTube

SAL067 + Alogliptin + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Jun 13, 2019 โ†’ Mar 25, 2022

NCT ID
NCT05782192

About SAL067 + Alogliptin + Placebo

SAL067 + Alogliptin + Placebo is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT05782192. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05782192Phase 3Completed

Competing Products

20 competing products in Diabetes Mellitus, Type 2

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Shenzhen Salubris Pharmaceuticals

Allisartan Isoproxil Tablets 240mg or placebo + Allisartan Isoproxil Tablets 480mg or placebo + Allisartan Isoproxil Tablets 720mg or placeboApproved
84
Enarodustat 2mg + Enarodustat 3mg + Enarodustat 4mgApproved
84
ClopidogrelApproved
84
SAL056 (56.5ฮผg) + AlendronatePhase 3
76
SAL-0951 + PlaceboPhase 3
76